Plantar heel pain / plantar fasciopathy · Randomized trial · 2022
Does treating points in the leg and pelvis help heel pain more than treating the heel?
In this trial, both ways of giving focused shockwave were followed by better foot scores. People treated on points along the leg and pelvis improved more: by four months their foot problem score (0–100) had dropped about twice as much as with treatment at the heel.
Possible early help from treating leg and pelvis points- adults with long-lasting heel pain
- 30
- sessions, one a week, in both groups
- 3
- after the last session
- 4 mo
Good to know: Only the leg and pelvis group also received manual release.
Tognolo L, Giordani F, Biz C, et al. European Journal of Physical and Rehabilitation Medicine, 2022 · Read the paper ↗
How this study worked
What happened
Foot problems: leg and pelvis points vs heel
Difference in change, 0–100 foot score, with likely range · below 0 favours leg and pelvis points
Show the numbers
| Difference (points on the 0–100 foot problem score) | likely range | |
|---|---|---|
| After 1 session | −3.9 | −20 to 12.1 |
| After 2 sessions | −18.9 | −35 to −2.9 |
| 1 month after | −20.7 | −37.3 to −4.1 |
| 4 months after | −19.9 | −36.7 to −3.2 |
The treatment
Shockwave on leg and pelvis points
Focused, once a week for 3 weeks
- Sessions
- 3, one a week
- Pulses
- 1,500 per point · 3 or 4 points on the leg and pelvis
- Strength
- 0.05–0.167mJ/mm² · 5 per second
- Numbing
- Not mentioned
- Device
- Duolith SD1 T-Top (Storz Medical)
- Everyone also got
- Manual release of a point if it had not loosened
Shockwave at the heel
Focused, once a week for 3 weeks
- Sessions
- 3, one a week
- Pulses
- 2,000 per point · the most tender spot on the heel
- Strength
- 0.20–0.32mJ/mm² · 5 per second
- Numbing
- Not mentioned
- Device
- Duolith SD1 T-Top (Storz Medical)
Compared with: The same focused shockwave given at the most tender spot on the heel
Settings are what each study used, not a prescription.
Who took part
30 adults in Padua, Italy, with heel pain for at least 3 months despite other care; the leg-point group had fewer women (45% vs 84%).
hollow squares: no final score
Side effects
The study does not report side effects.
All the numbers and the full appraisal
The results, in numbers.
Adults at one Padua outpatient clinic (April 2019–February 2020) with plantar fasciitis for ≥3 months despite drugs, exercise or insoles, and pain ≥5 on VAS. Mean age 54.7 versus 59.3 years; women 45.5% versus 84.2%. Previous foot fracture or surgery, steroid injection within 3 months, diabetes, vascular disease and suspected fibromyalgia were excluded.
People; all 11 received the allocated treatment and were analysed. If a patient had bilateral symptoms, the most symptomatic foot was scored.
People; 4 dropped out (1 after the second and 3 after the third session; Figure 1: 1 lost to follow-up, 3 discontinued, reasons not given) and were excluded from analysis. Table I is headed N=15 but its sex counts add to 19.
Foot function (17-iFFI)4 reported outcomes
Foot function (17-iFFI)
17-Italian Foot Function Index (17-iFFI) Score points, change from baseline (T1)
| Group | n | Baseline | Reported change |
|---|---|---|---|
| ESWT on myofascial points | 11 | — | -10.5 (SD 12.6) |
| ESWT at the heel | 15 | — | -6.6 (SD 11.6) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Myofascial-point ESWT minus heel ESWT
Mixed model on change from baseline (group, time, group×time, first-order autoregressive covariance); least-squares means with Bonferroni-adjusted 95% CI and P
17-iFFI fell in both groups. The model favoured the myofascial-point group overall (group effect P=0.0016; interaction P=0.0926), with adjusted differences significant at T3, T4 and T5 but not at T2. These are differences in change between two active shockwave approaches among the 26 people analysed.
Analysis details and source
Group columns are observed mean (SD) change from baseline; the effect is the model estimate. Completers only: 11 versus 15 of 30 randomized. 17-iFFI: 0 best, 100 worst; range 0–100 per Methods p. 88. Gender-adjusted analysis reported as similar, data not shown.
Foot function (17-iFFI)
17-Italian Foot Function Index (17-iFFI) Score points, change from baseline (T1)
| Group | n | Baseline | Reported change |
|---|---|---|---|
| ESWT on myofascial points | 11 | — | -21.8 (SD 23) |
| ESWT at the heel | 15 | — | -2.9 (SD 8.5) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Myofascial-point ESWT minus heel ESWT
Mixed model on change from baseline (group, time, group×time, first-order autoregressive covariance); least-squares means with Bonferroni-adjusted 95% CI and P
17-iFFI fell in both groups. The model favoured the myofascial-point group overall (group effect P=0.0016; interaction P=0.0926), with adjusted differences significant at T3, T4 and T5 but not at T2. These are differences in change between two active shockwave approaches among the 26 people analysed.
Analysis details and source
Group columns are observed mean (SD) change from baseline; the effect is the model estimate. Completers only: 11 versus 15 of 30 randomized. 17-iFFI: 0 best, 100 worst; range 0–100 per Methods p. 88. Gender-adjusted analysis reported as similar, data not shown.
Foot function (17-iFFI)
17-Italian Foot Function Index (17-iFFI) Score points, change from baseline (T1)
| Group | n | Baseline | Reported change |
|---|---|---|---|
| ESWT on myofascial points | 11 | — | -36.1 (SD 24.2) |
| ESWT at the heel | 15 | — | -15.41 (SD 12.1) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Myofascial-point ESWT minus heel ESWT
Mixed model on change from baseline (group, time, group×time, first-order autoregressive covariance); least-squares means with Bonferroni-adjusted 95% CI and P
17-iFFI fell in both groups. The model favoured the myofascial-point group overall (group effect P=0.0016; interaction P=0.0926), with adjusted differences significant at T3, T4 and T5 but not at T2. These are differences in change between two active shockwave approaches among the 26 people analysed.
Analysis details and source
Group columns are observed mean (SD) change from baseline; the effect is the model estimate. Completers only: 11 versus 15 of 30 randomized. 17-iFFI: 0 best, 100 worst; range 0–100 per Methods p. 88. Gender-adjusted analysis reported as similar, data not shown.
Foot function (17-iFFI)
17-Italian Foot Function Index (17-iFFI) Score points, change from baseline (T1)
| Group | n | Baseline | Reported change |
|---|---|---|---|
| ESWT on myofascial points | 11 | — | -40.5 (SD 26.8) |
| ESWT at the heel | 15 | — | -20.5 (SD 14.6) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Myofascial-point ESWT minus heel ESWT
Mixed model on change from baseline (group, time, group×time, first-order autoregressive covariance); least-squares means with Bonferroni-adjusted 95% CI and P
17-iFFI fell in both groups. The model favoured the myofascial-point group overall (group effect P=0.0016; interaction P=0.0926), with adjusted differences significant at T3, T4 and T5 but not at T2. These are differences in change between two active shockwave approaches among the 26 people analysed.
Analysis details and source
Group columns are observed mean (SD) change from baseline; the effect is the model estimate. Completers only: 11 versus 15 of 30 randomized. 17-iFFI: 0 best, 100 worst; range 0–100 per Methods p. 88. Gender-adjusted analysis reported as similar, data not shown.
Foot and ankle outcome (FAOS)4 reported outcomes
Foot and ankle outcome (FAOS)
Foot and Ankle Outcome Score (FAOS) Score points, change from baseline (T1)
| Group | n | Baseline | Reported change |
|---|---|---|---|
| ESWT on myofascial points | 11 | — | 6.5 (SD 16.7) |
| ESWT at the heel | 15 | — | 3.9 (SD 4.9) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Myofascial-point ESWT minus heel ESWT
Mixed model on change from baseline (group, time, group×time, first-order autoregressive covariance); least-squares means with Bonferroni-adjusted 95% CI and P
FAOS rose in both groups. The model favoured the myofascial-point group (group effect P=0.0072; interaction P=0.0143), with adjusted differences significant at T3, T4 and T5 but not at T2. The four control dropouts are not in these estimates.
Analysis details and source
Group columns are observed mean (SD) change from baseline; the effect is the model estimate. Completers only: 11 versus 15 of 30 randomized. FAOS: 0 worst, 100 best; range 0–100 per Methods p. 88. Gender-adjusted analysis reported as similar, data not shown.
Foot and ankle outcome (FAOS)
Foot and Ankle Outcome Score (FAOS) Score points, change from baseline (T1)
| Group | n | Baseline | Reported change |
|---|---|---|---|
| ESWT on myofascial points | 11 | — | 15.4 (SD 14.8) |
| ESWT at the heel | 15 | — | 0.7 (SD 8.8) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Myofascial-point ESWT minus heel ESWT
Mixed model on change from baseline (group, time, group×time, first-order autoregressive covariance); least-squares means with Bonferroni-adjusted 95% CI and P
FAOS rose in both groups. The model favoured the myofascial-point group (group effect P=0.0072; interaction P=0.0143), with adjusted differences significant at T3, T4 and T5 but not at T2. The four control dropouts are not in these estimates.
Analysis details and source
Group columns are observed mean (SD) change from baseline; the effect is the model estimate. Completers only: 11 versus 15 of 30 randomized. FAOS: 0 worst, 100 best; range 0–100 per Methods p. 88. Gender-adjusted analysis reported as similar, data not shown.
Foot and ankle outcome (FAOS)
Foot and Ankle Outcome Score (FAOS) Score points, change from baseline (T1)
| Group | n | Baseline | Reported change |
|---|---|---|---|
| ESWT on myofascial points | 11 | — | 23.1 (SD 14.1) |
| ESWT at the heel | 15 | — | 10.5 (SD 10) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Myofascial-point ESWT minus heel ESWT
Mixed model on change from baseline (group, time, group×time, first-order autoregressive covariance); least-squares means with Bonferroni-adjusted 95% CI and P
FAOS rose in both groups. The model favoured the myofascial-point group (group effect P=0.0072; interaction P=0.0143), with adjusted differences significant at T3, T4 and T5 but not at T2. The four control dropouts are not in these estimates.
Analysis details and source
Group columns are observed mean (SD) change from baseline; the effect is the model estimate. Completers only: 11 versus 15 of 30 randomized. FAOS: 0 worst, 100 best; range 0–100 per Methods p. 88. Gender-adjusted analysis reported as similar, data not shown.
Foot and ankle outcome (FAOS)
Foot and Ankle Outcome Score (FAOS) Score points, change from baseline (T1)
| Group | n | Baseline | Reported change |
|---|---|---|---|
| ESWT on myofascial points | 11 | — | 26.9 (SD 18.5) |
| ESWT at the heel | 15 | — | 12.9 (SD 11.4) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Myofascial-point ESWT minus heel ESWT
Mixed model on change from baseline (group, time, group×time, first-order autoregressive covariance); least-squares means with Bonferroni-adjusted 95% CI and P
FAOS rose in both groups. The model favoured the myofascial-point group (group effect P=0.0072; interaction P=0.0143), with adjusted differences significant at T3, T4 and T5 but not at T2. The four control dropouts are not in these estimates.
Analysis details and source
Group columns are observed mean (SD) change from baseline; the effect is the model estimate. Completers only: 11 versus 15 of 30 randomized. FAOS: 0 worst, 100 best; range 0–100 per Methods p. 88. Gender-adjusted analysis reported as similar, data not shown.
How treatment was delivered
Focused shockwaves from a Duolith SD1 T-Top device (Storz Medical), three sessions one week apart in both arms. Anaesthesia was not reported.
Before each session, 3 or 4 myofascial points of the lower limbs and pelvis were chosen by Fascial Manipulation (Stecco) palpation; 1,500 shocks per point at 5 Hz and 0.05–0.167 mJ/mm², set by pain threshold. If a point had not loosened, treatment was completed manually until release.
2,000 shocks at 0.20–0.32 mJ/mm² (by pain threshold) and 5 Hz over one spot, the point of maximal tenderness on the medial calcaneal tubercle. This is an active comparator, not a sham.
Manual completion of myofascial release was allowed only in the experimental arm. Other co-treatments, medication rules and exercise advice were not reported.
Adverse events were not reported for either group. The authors say only that adverse effects are extremely rare at the energy chosen; this is a statement, not a count, so harms are unknown rather than zero. Reasons for the four control dropouts were not given. Conflicts of interest: none declared. Funding: not stated.
Author-reported: unequal numbers analysed per group, follow-up too short to study recurrence, and different shock counts between arms (1,500 per point at 3–4 points versus 2,000 at one spot).
Extractor interpretation: open-label design with self-reported questionnaires; simple Excel RAND allocation without described concealment produced 11 versus 19; only the 26 completers were analysed and all four dropouts were in the heel group, which can bias the comparison.
Extractor interpretation: the experimental arm could also receive manual myofascial release, energy ranges differed, and women were 45.5% versus 84.2% of the groups, so the contrast is not the treatment site alone.
Reporting: ClinicalTrials.gov NCT05090059 was first submitted on 6 September 2021, after enrolment ended in February 2020 (registry record checked). No primary outcome is named in the paper; the registry lists both scales. Table I is headed control N=15 while its sex counts total 19, and Table III labels the comparison "EG vs. TG".
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- Author-reported: unequal numbers analysed per group, follow-up too short to study recurrence, and different shock counts between arms (1,500 per point at 3–4 points versus 2,000 at one spot).
- Extractor interpretation: open-label design with self-reported questionnaires; simple Excel RAND allocation without described concealment produced 11 versus 19; only the 26 completers were analysed and all four dropouts were in the heel group, which can bias the comparison.
- Extractor interpretation: the experimental arm could also receive manual myofascial release, energy ranges differed, and women were 45.5% versus 84.2% of the groups, so the contrast is not the treatment site alone.
- Reporting: ClinicalTrials.gov NCT05090059 was first submitted on 6 September 2021, after enrolment ended in February 2020 (registry record checked). No primary outcome is named in the paper; the registry lists both scales. Table I is headed control N=15 while its sex counts total 19, and Table III labels the comparison "EG vs. TG".
Source-linked critical reading
Open-label randomized trial of two focused-shockwave targets
Technical source record
Full local PDF read: all 9 pages including Tables I–III from page images, Figures 1–4 and captions, Methods, Results, Discussion, Limitations, conflicts of interest and references; trial registry dates checked.
In this open-label trial in Italy, both ways of giving focused shockwaves were followed by better foot scores. People treated on myofascial points of the leg and pelvis improved more than people treated at the heel from the second week to four months. All dropouts were in the heel group, manual release was added only in the other group, and harms were not reported, so this comparison needs confirmation.
In adults with persistent plantar fasciitis, do focused shockwaves aimed at myofascial points of the leg and pelvis improve foot function more than focused shockwaves at the painful heel?
Open-label randomized trial at one Italian outpatient clinic. Excel RAND allocation produced groups of 11 and 19; all received treatment, 4 control patients dropped out and 26 were analysed (11 versus 15). Registration (NCT05090059) was submitted in September 2021, after enrolment had ended.
Adults at one Padua outpatient clinic (April 2019–February 2020) with plantar fasciitis for ≥3 months despite drugs, exercise or insoles, and pain ≥5 on VAS. Mean age 54.7 versus 59.3 years; women 45.5% versus 84.2%. Previous foot fracture or surgery, steroid injection within 3 months, diabetes, vascular disease and suspected fibromyalgia were excluded.
Three weekly sessions with a Duolith SD1 T-Top focused device. Before each session 3–4 myofascial points of the lower limbs and pelvis were chosen by Fascial Manipulation palpation and each received 1,500 shocks at 5 Hz and 0.05–0.167 mJ/mm². Points not released by the shocks were finished by hand.
The control group received focused shockwaves at the most tender spot on the medial calcaneal tubercle: 2,000 shocks at 0.20–0.32 mJ/mm² and 5 Hz, weekly for three sessions. Both groups had active treatment; there was no sham or untreated group.
Two self-reported questionnaires, the 17-item Italian Foot Function Index (0 best, 100 worst) and the FAOS (0 worst, 100 best), were filled in at baseline, before the second and third sessions, and one and four months after the last session. Analyses used change from baseline in a mixed model. The paper names no single primary outcome.
Both groups improved. At one week neither scale differed. From the assessment before the third session (T3) onward the myofascial-point group had larger gains: 17-iFFI adjusted differences −18.9 (95% CI −35.0 to −2.9) at T3, −20.7 (−37.3 to −4.1) at one month and −19.9 (−36.7 to −3.2) at four months; FAOS differences 14.6 (2.8 to 26.5), 12.8 (0.7 to 25.0) and 14.2 (1.9 to 26.5). Wide intervals reflect the small groups, and the four control dropouts are excluded.
Adverse events were not reported for either group. The authors say only that adverse effects are extremely rare at the energy chosen; this is a statement, not a count, so harms are unknown rather than zero. Reasons for the four control dropouts were not given. Conflicts of interest: none declared. Funding: not stated.
Open-label self-report, unequal allocation (11 versus 19) without described concealment, and a completers-only analysis with every dropout in the heel group. The experimental arm could also get manual release, energy and shock counts differed, and sex distribution was unbalanced. Registration came after enrolment, no primary outcome is named, Table I lists control N=15 while its sex counts total 19, and follow-up ends at four months.
Applies to adults with chronic plantar fasciitis treated by clinicians trained in Fascial Manipulation, comparing two focused-shockwave strategies. It does not compare shockwaves with sham, exercise or usual care, and it does not show which part of the experimental package (site, energy or manual release) mattered.
A larger prospectively registered trial with concealed allocation, blinded assessors, matched energy and no added manual therapy, analysing everyone randomized, recording adverse events and following people for a year or more.
Read the original article.
Myofascial points treatment with focused extracorporeal shock wave therapy (f-ESWT) for plantar fasciitis: an open label randomized clinical trial.
Tognolo L, Giordani F, Biz C, Bernini A, Ruggieri P, Stecco C, Frigo AC, Masiero S. · European journal of physical and rehabilitation medicine · 2022
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →